

### CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide

Mouse Monoclonal Antibody [Clone HuLy-m13]
Catalog # AH12855

### **Specification**

## CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide - Product Information

Application ,3,4,
Reactivity Human
Host Mouse
Clonality Monoclonal
Isotype Mouse / IgM
Calculated MW Not known KDa

## CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide - Additional Information

#### **Storage**

Store at 2 to 8°C. Antibody is stable for 24 months.

### **Precautions**

CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures.

# CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide - Protein Information

#### CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

## CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide - Images

### CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide - Background

CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down





regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor  $\bar{l}$  (TNF $\bar{l}$  (TNF $\bar{l}$ )-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization.

### CDw17 (Lactosylceramide or LacCer) Antibody - With BSA and Azide - References

Lovering, K.E. Characterisation of the Tcell surface by monoclonal antibodies. PhD thesis, University of Melbourne, 1985. | Knapp W. Leukocyte Typing IV, Oxford Univ. Press, pp. 810811, 1989. Also data on M119, pp 861, 874, 877 879, 897, 907, 923, 925